FDA
This article was originally published in The Rose Sheet
Executive Summary
Former Office of Review Management Director Murray Lumpkin, MD, appointed acting deputy commissioner, making him the agency's highest ranking physician. Lumpkin will serve as acting Commissioner Schwetz' principal deputy in the near-term and may be in a position to continue in that role if HHS' selection for the commissioner post, former Center for Veterinary Medicine Director Lester Crawford, PhD, is confirmed (1"The Rose Sheet" Oct. 1, p. 7). Lumpkin, whose "position of record" will be senior associate commissioner for international activities and strategic initiatives, overseeing the Office of International Programs, is credited as one of the principle architects of FDA's faster, more predictable drug review performance during the 1990s
You may also be interested in...
FDA Commish Pick OK With Kennedy, Thompson Says; Bush Nod Awaited
Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, DVM/PhD, may represent the Bush administration's last chance to nominate an FDA commissioner this year.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle